Cependant, ils doivent être présents aux côtés des patientes pendant toute la durée de l'injection sous-cutanée (5 minutes) ,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre Partie 1 ? Tumeurs solides. Saint-Maurice (Fra) : Institut de veille sanitaire, 1980. ,
Available from: http://www.cancer-environnement.fr/478-Classification-des-substances- cancerogenes.ce.aspx 11. Quelques chiffres -Cancer du sein | Institut National Du Cancer, 2016. ,
Grosclaude Survie des personnes atteintes de cancer en France métropolitaine, 1989. ,
DOI : 10.1016/j.respe.2016.06.084
Apport du couple écho-mammographie dans le diagnostic des cancers du sein A propos de 100 cas Available from: http://wd.fmpm.uca.ma/biblio/theses/annee-htm/FT, pp.67-82, 2015. ,
Available from: http://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du- sein/Facteurs-de-risque, Cancer du sein | Institut National Du Cancer [Internet], 2016. ,
Oophorectomy in Breast Cancer???Controversies and Current Status, Indian Journal of Surgery, vol.29, issue.3, pp.210-212 ,
DOI : 10.1007/s12262-012-0584-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397181
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer Available from, Curr Treat Options Oncol [Internet], vol.18, issue.1, pp.11864-11881, 2017. ,
Available from: http://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du- sein, Institut National Du Cancer [Internet], 2016. ,
Th?rapie cibl?e et cancer du sein?: ?tat de l?art, Pathologie Biologie, vol.60, issue.4, pp.254-63, 2012. ,
DOI : 10.1016/j.patbio.2012.05.012
HER-2 Signaling and Inhibition in Breast Cancer, Current Cancer Drug Targets, vol.9, issue.3, pp.419-457, 2009. ,
DOI : 10.2174/156800909788166484
Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Research, vol.49, issue.2, p.1, 2014. ,
DOI : 10.1186/bcr3621
Pertuzumab: une nouvelle option thérapeutique dans le traitement des cancers du sein HER2, Lett Cancérologue, vol.21, issue.10, pp.492-498, 2012. ,
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer, Breast Care, vol.8, issue.1, pp.49-55, 2013. ,
DOI : 10.1159/000346837
Available from: https ,
Available from: https://www.sante-ra.fr/accueil/sisra-a-votre-services-patients-et-usagers ,
Réseau Espace Santé Cancer Rhône-Alpes [Internet]. [cited 2017 Feb 6] Available from ,
Améliorer la coordination des soins : comment faire évoluer les réseaux de santé ?. Direction générale de l'offre de soins, 2012. ,
Available from: http://www.roche.fr/patients/info-patients-cancer/traitement-cancer/traitementchimiotherapie/chimiotherapie-orale .html 69, HAS : Conditions et développement de la chimiothérapie en hospitalisation à domicile : analyse économique et organisationnelle-janvier 2015.pdf, 2017. ,
Avis 2 avril 2014. HERCEPTIN 600 mg/5 ml, solution injectable Flacon de 6 ml, Laboratoire ROCHE SAS ,
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer, The Journal of Clinical Pharmacology, vol.20, issue.2, pp.192-201, 2013. ,
DOI : 10.1177/0091270012436560
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-92, 2001. ,
DOI : 10.1056/NEJM200103153441101
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I?III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial, The Lancet Oncology, vol.13, issue.9, pp.869-78, 2012. ,
DOI : 10.1016/S1470-2045(12)70329-7
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study, Annals of Oncology, vol.25, issue.10, pp.1979-87, 2014. ,
DOI : 10.1093/annonc/mdu364
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study, The Lancet Oncology, vol.14, issue.10, pp.962-70, 2013. ,
DOI : 10.1016/S1470-2045(13)70383-8
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males, Cancer Chemotherapy and Pharmacology, vol.5, issue.5, 2013. ,
DOI : 10.1007/s00280-013-2273-z
la nouvelle formulation sous-cutanée d'Herceptin-Laboratoire ROCHE SAS, 2013. ,
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer, Cancer Med. 2016, vol.5, issue.3, pp.389-97 ,